Ironwood Q2 revenue rises 33%

Ironwood Pharmaceuticals

06/08/2026 12:40

Overview
U.S. biotech firm's Q2 revenue rose 33% yr/yr but missed analyst expectations
Adjusted EBITDA for Q2 missed analyst expectations
Company raised 2026 guidance for LINZESS net sales, total revenue, and adjusted EBITDA

Outlook
Ironwood raises 2026 U.S. LINZESS net sales guidance to $1.15-$1.20 bln
Company lifts 2026 total revenue guidance to $460-$485 mln
Ironwood increases 2026 adjusted EBITDA guidance to greater than $310 mln

Result Drivers
LINZESS NET SALES - Co said Q2 sales growth was driven by improved net price and mid-single digit prescription demand growth
REBATE IMPACT - Elimination of inflationary rebates and favorable time-phasing of gross-to-net rebate reserves contributed to higher LINZESS net sales
PEDIATRIC APPROVAL - FDA approval for LINZESS in pediatric patients expanded market and supported demand growth

Company press release: ID:nBw3Ksx8Ba

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$113.04 mln
$114.84 mln (4 Analysts)
Q2 EPS
 
$0.31
 
Q2 Adjusted Net Income
Beat
$51.50 mln
$45.95 mln (2 Analysts)
Q2 Net Income
 
$51.29 mln
 
Q2 Adjusted EBITDA
Miss
$83.04 mln
$84.43 mln (3 Analysts)
Q2 Basic EPS
 
$0.31
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Ironwood Pharmaceuticals, Inc. is $5.35, about 28.9% above its August 5 closing price of $4.15
The stock recently traded at 3 times the next 12-month earnings vs. a P/E of 3 three months ago

Reuters Recommended Reads
Aug 5 - Mirum Pharmaceuticals Q2 sales rise, lifts outlook
Aug 4 - Acadia Pharmaceuticals Q2 revenue rises on DAYBUE STIX demand, lifts 2026 outlook
Aug 5 - Exelixis Q2 revenue misses analyst estimates, lowers 2026 outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)